Amol Akhade, Senior Medical and Hemato-Oncologist based in Mumbai, India, shared a post on LinkedIn:
“LET’S PLAY DEVIL’S ADVOCATE:
Should CDK4/6 inhibitors be standard in early HR+/HER2– breast cancer? Tannock et al. JCO_ASCO argue –
Modest iDFS, no OS benefit ( yet ) , high toxicity and censoring bias.
I broke it down—with counterarguments .
Do Check this out.”
Authors: Ian F. Tannock, Qamar J. Khan, and Tito Fojo
More posts featuring Amol Akhade.
